

- Steroid use (>250 mg hydrocortisone, >50 mg methylprednisolone, >60 mg prednisone, >10 mg dexamethasone)
- Occult blood lasting more than 6 days

Exclusions for automatic discontinuation of treatment with PPI/H2RA/sucralfate:

- Use of a PPI/H2RA/sucralfate prior to admission
- Patient with ICU status
- Acute upper GI bleed
- Erosive esophagitis
- H. pylori treatment
- Gastric or duodenal ulcer
- GERD
- Zollinger-Ellison Syndrome
- Orders for Continuous Infusions of PPI's or H2RA's
- Anemia / Positive stool blood occult
- The comment 'do not auto discontinue' in the original order

3. If patient meets criteria for automatic discontinuation of stress ulcer prophylaxis therapy, the evaluating pharmacist will discontinue therapy in HEO and document in the electronic medical record.

- Any questionable PPI/H2RA/sucralfate use will need to be discussed with the primary team before automatic discontinuation by a pharmacist
- By writing "do not auto discontinue" in the HEO comments, physicians can prevent automatic discontinuation of therapy

References:

1. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999;56(4):347-379.

Approved by:		Review/Revision Date: 5/16 5/19 4/22
<u>/s/</u>	<u>04/25/2022</u>	
Lindsey Eitnrear, PharmD, BCPS, AAHIVP Director of Pharmacy	Date	
<u>/s/</u>	<u>04/25/2022</u>	
Russell Smith, PharmD, MBA, BCPS Senior Hospital Administrator	Date	
<u>/s/</u>	<u>04/25/2022</u>	
Zohaib Ahmed, MD Chair of Pharmacy & Therapeutics Committee	Date	
Review/Revision Completed By: Pharmacy		
		Next Review Date: 4/1/2025

Policies Superseded by This Policy:

It is the responsibility of the reader to verify with the responsible agent that this is the most current version of the policy.